

Table 3: Stepwise multivariate linear regression analysis taking into account the use of proton pump inhibitors (PPIs) and other factors affecting the changes of lipid parameters.

Regressors	LDL-C reduction (beta/p)
Baseline LDL-C	0.482 (<0.001)
Ezetimibe	0.198 (<0.001)
Diabetes	0.168 (<0.001)
Compliance with lipid-lowering therapy	0.205 (<0.001)
PPIs	0.104 (0.005)
Intensity of statin therapy [†]	0.101 (0.009)
CV risk [‡]	0.082 (0.049)
R ² X 100	43.2

[†]: Intensity of statin treatment is based on the average expected low-density lipoprotein cholesterol reduction (≥ 50 , 30-50 and $< 30\%$, respectively)¹⁴. [‡]: Cardiovascular risk was classified according to European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines for the management of dyslipidemias³. LDL-C: low-density lipoprotein cholesterol, PPIs: proton pump inhibitors, CV: cardiovascular.